Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04884308 · ClinicalTrials.gov registry record · Phase 2
Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04884308: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT04884308 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04884308, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.
Interventions
- BIOLOGICAL BCG TICE Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04884308
The ClinicalTrials.gov registry entry for NCT04884308 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BCG TICE Vaccine is the first listed.
NCT04884308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04884308 about?
NCT04884308 is a clinical study titled "Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections". This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.
What is the current status of trial NCT04884308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-04-28. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04884308?
The interventions under investigation include: BCG TICE Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04884308?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.